Header Logo

Connection

Usman Baber to Middle Aged

Back to Details
This is a "connection" page, showing publications Usman Baber has written about Middle Aged.
Usman Baber
Connection Strength
3.373
Middle Aged
  1. Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy. J Am Coll Cardiol. 2020 02 18; 75(6):578-586.
    View in: PubMed
    Score: 0.078
  2. Ventricular Fibrillation Associated With Coronary Plaque Erosion Detected by Optical Coherence Tomography. JACC Cardiovasc Interv. 2020 01 13; 13(1):e5-e7.
    View in: PubMed
    Score: 0.077
  3. Impact of Diabetes Mellitus in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. Circ Cardiovasc Interv. 2019 07; 12(7):e007734.
    View in: PubMed
    Score: 0.075
  4. Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk. Circ Cardiovasc Qual Outcomes. 2019 01; 12(1):e004945.
    View in: PubMed
    Score: 0.072
  5. Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention: Results From the PARIS Registry (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients). Circ Cardiovasc Interv. 2018 03; 11(3):e006144.
    View in: PubMed
    Score: 0.068
  6. Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study. JACC Cardiovasc Interv. 2017 10 23; 10(20):2017-2025.
    View in: PubMed
    Score: 0.065
  7. Use of prasugrel vs clopidogrel and outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention in contemporary clinical practice: Results from the PROMETHEUS study. Am Heart J. 2017 Jun; 188:73-81.
    View in: PubMed
    Score: 0.063
  8. Comparisons of the uptake and in-hospital outcomes associated with second-generation drug-eluting stents between men and women: results from the CathPCI Registry. Coron Artery Dis. 2016 Sep; 27(6):442-8.
    View in: PubMed
    Score: 0.061
  9. Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention: Results From the PARIS Registry. JACC Cardiovasc Interv. 2016 07 11; 9(13):1349-57.
    View in: PubMed
    Score: 0.061
  10. Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. J Am Coll Cardiol. 2016 May 17; 67(19):2224-2234.
    View in: PubMed
    Score: 0.060
  11. Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: A Patient-Level Pooled Analysis of Randomized Controlled Trials. JACC Cardiovasc Interv. 2016 Jan 11; 9(1):28-38.
    View in: PubMed
    Score: 0.059
  12. Prevalence and impact of high platelet reactivity in chronic kidney disease: results from the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents registry. Circ Cardiovasc Interv. 2015 Jun; 8(6):e001683.
    View in: PubMed
    Score: 0.056
  13. Prevalence, impact, and predictive value of detecting subclinical coronary and carotid atherosclerosis in asymptomatic adults: the BioImage study. J Am Coll Cardiol. 2015 Mar 24; 65(11):1065-74.
    View in: PubMed
    Score: 0.055
  14. Risk for recurrent coronary heart disease and all-cause mortality among individuals with chronic kidney disease compared with diabetes mellitus, metabolic syndrome, and cigarette smokers. Am Heart J. 2013 Aug; 166(2):373-380.e2.
    View in: PubMed
    Score: 0.049
  15. Combined and independent impact of diabetes mellitus and chronic kidney disease on residual platelet reactivity. Thromb Haemost. 2013 Jul; 110(1):118-23.
    View in: PubMed
    Score: 0.049
  16. Coronary plaque composition, morphology, and outcomes in patients with and without chronic kidney disease presenting with acute coronary syndromes. JACC Cardiovasc Imaging. 2012 Mar; 5(3 Suppl):S53-61.
    View in: PubMed
    Score: 0.045
  17. Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials. J Am Coll Cardiol. 2011 Oct 04; 58(15):1569-77.
    View in: PubMed
    Score: 0.043
  18. Association of chronic kidney disease with atrial fibrillation among adults in the United States: REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Circ Arrhythm Electrophysiol. 2011 Feb; 4(1):26-32.
    View in: PubMed
    Score: 0.041
  19. Efficacy of modified dual antiplatelet therapy combined with warfarin following percutaneous coronary intervention with drug-eluting stents. J Invasive Cardiol. 2010 Feb; 22(2):80-3.
    View in: PubMed
    Score: 0.039
  20. Combined role of reduced estimated glomerular filtration rate and microalbuminuria on the prevalence of peripheral arterial disease. Am J Cardiol. 2009 Nov 15; 104(10):1446-51.
    View in: PubMed
    Score: 0.038
  21. Thrombolysis In Myocardial Infarction (TIMI) risk score and mortality in patients with advanced chronic kidney disease and on dialysis. Am J Cardiol. 2009 Jun 01; 103(11):1513-7.
    View in: PubMed
    Score: 0.037
  22. Non-traditional risk factors predict coronary calcification in chronic kidney disease in a population-based cohort. Kidney Int. 2008 Mar; 73(5):615-21.
    View in: PubMed
    Score: 0.033
  23. Mortality After Procedural or Spontaneous Myocardial Infarction. J Am Coll Cardiol. 2024 Jul 30; 84(5):467-477.
    View in: PubMed
    Score: 0.026
  24. Antithrombotic strategy variability in atrial fibrillation and obstructive coronary disease revascularised with percutaneous coronary intervention: primary results from the AVIATOR 2 international registry. EuroIntervention. 2022 Oct 07; 18(8):e656-e665.
    View in: PubMed
    Score: 0.023
  25. A contemporary simple risk score for prediction of contrast-associated acute kidney injury after percutaneous coronary intervention: derivation and validation from an observational registry. Lancet. 2021 11 27; 398(10315):1974-1983.
    View in: PubMed
    Score: 0.022
  26. Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention: A Subgroup Analysis of the TWILIGHT Randomized Clinical Trial. JAMA Cardiol. 2021 09 01; 6(9):1032-1041.
    View in: PubMed
    Score: 0.022
  27. P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials. BMJ. 2021 06 16; 373:n1332.
    View in: PubMed
    Score: 0.021
  28. Relationship between high shear stress and OCT-verified thin-cap fibroatheroma in patients with coronary artery disease. PLoS One. 2020; 15(12):e0244015.
    View in: PubMed
    Score: 0.021
  29. Prevalence and prognostic impact of hsCRP elevation are age-dependent in women but not in men undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv. 2021 06 01; 97(7):E936-E944.
    View in: PubMed
    Score: 0.021
  30. Impact of High-Density Lipoprotein Levels on Cardiovascular Outcomes of Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. Am J Cardiol. 2020 12 15; 137:1-6.
    View in: PubMed
    Score: 0.020
  31. Validation of the Academic Research Consortium High Bleeding Risk Definition in Contemporary PCI Patients. J Am Coll Cardiol. 2020 06 02; 75(21):2711-2722.
    View in: PubMed
    Score: 0.020
  32. Trends and Outcomes of Intravascular Imaging-guided Percutaneous Coronary Intervention in the United States. Crit Pathw Cardiol. 2020 06; 19(2):69-74.
    View in: PubMed
    Score: 0.020
  33. Ticagrelor monotherapy in patients with diabetes mellitus undergoing percutaneous coronary interventions: insights from the TWILIGHT trial. Cardiovasc Res. 2020 06 01; 116(7):e70-e72.
    View in: PubMed
    Score: 0.020
  34. Sleep Duration and Cardiovascular Health in a Representative Community Population (from NHANES, 2005 to 2016). Am J Cardiol. 2020 07 15; 127:149-155.
    View in: PubMed
    Score: 0.020
  35. Comparison of One-Year Outcomes in Patients >75 Versus =75 Years With Coronary Artery Disease Treated With COMBO Stents (From The MASCOT Registry). Am J Cardiol. 2020 07 15; 127:1-8.
    View in: PubMed
    Score: 0.020
  36. Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y12 Receptor Inhibitors With and Without Aspirin: Results of the VORA-PRATIC Study. J Am Heart Assoc. 2020 04 21; 9(8):e015865.
    View in: PubMed
    Score: 0.020
  37. 1-Year Clinical Outcomes of All Comers Treated With 2 Bioresorbable Polymer-Coated Sirolimus-Eluting Stents: Propensity Score-Matched Comparison of the COMBO and Ultrathin-Strut Orsiro Stents. JACC Cardiovasc Interv. 2020 04 13; 13(7):820-830.
    View in: PubMed
    Score: 0.020
  38. A missense variant in Mitochondrial Amidoxime Reducing Component 1 gene and protection against liver disease. PLoS Genet. 2020 04; 16(4):e1008629.
    View in: PubMed
    Score: 0.020
  39. Ticagrelor With or Without Aspirin After Complex PCI. J Am Coll Cardiol. 2020 05 19; 75(19):2414-2424.
    View in: PubMed
    Score: 0.020
  40. Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention: The PARIS Registry. Circ Cardiovasc Interv. 2020 04; 13(4):e008226.
    View in: PubMed
    Score: 0.020
  41. Clinical features and prognosis of patients with spontaneous coronary artery dissection. Int J Cardiol. 2020 08 01; 312:33-36.
    View in: PubMed
    Score: 0.020
  42. Impact of insulin treated and non-insulin-treated diabetes compared to patients without diabetes on 1-year outcomes following contemporary PCI. Catheter Cardiovasc Interv. 2020 08; 96(2):298-308.
    View in: PubMed
    Score: 0.020
  43. Association between age and readmission after percutaneous coronary intervention for acute myocardial infarction. Heart. 2020 10; 106(20):1595-1603.
    View in: PubMed
    Score: 0.020
  44. Long-Term Safety and Efficacy of Durable Polymer Cobalt-Chromium Everolimus-Eluting Stents in Patients at High Bleeding Risk: A Patient-Level Stratified Analysis From Four Postapproval Studies. Circulation. 2020 03 17; 141(11):891-901.
    View in: PubMed
    Score: 0.019
  45. Prasugrel use and clinical outcomes by age among patients undergoing PCI for acute coronary syndrome: from the PROMETHEUS study. Clin Res Cardiol. 2020 Jun; 109(6):725-734.
    View in: PubMed
    Score: 0.019
  46. Impact of high on-treatment platelet reactivity on outcomes following PCI in patients on hemodialysis: An ADAPT-DES substudy. Catheter Cardiovasc Interv. 2020 10 01; 96(4):793-801.
    View in: PubMed
    Score: 0.019
  47. Ticagrelor with or without Aspirin in High-Risk Patients after PCI. N Engl J Med. 2019 11 21; 381(21):2032-2042.
    View in: PubMed
    Score: 0.019
  48. Impact of stent diameter on outcomes following percutaneous coronary intervention with second-generation drug-eluting stents: Results from a large single-center registry. Catheter Cardiovasc Interv. 2020 09 01; 96(3):558-564.
    View in: PubMed
    Score: 0.019
  49. Feasibility of measuring patient-reported health status at time of percutaneous coronary intervention: Results from a single-center quality-improvement initiative. Eur J Prev Cardiol. 2020 12; 27(19):2183-2186.
    View in: PubMed
    Score: 0.019
  50. Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry. Thromb Haemost. 2019 10; 119(10):1704-1711.
    View in: PubMed
    Score: 0.019
  51. Negative Risk Markers for Cardiovascular Events in the Elderly. J Am Coll Cardiol. 2019 07 09; 74(1):1-11.
    View in: PubMed
    Score: 0.019
  52. Associations between use of prasugrel vs clopidogrel and outcomes by type of acute coronary syndrome: an analysis from the PROMETHEUS registry. J Thromb Thrombolysis. 2019 Jul; 48(1):42-51.
    View in: PubMed
    Score: 0.019
  53. Incidence, predictors and impact of stroke on mortality among patients with acute coronary syndromes following percutaneous coronary intervention-Results from the PROMETHEUS registry. Catheter Cardiovasc Interv. 2020 04 01; 95(5):885-892.
    View in: PubMed
    Score: 0.019
  54. Incidence, determinants and impact of acute kidney injury in patients with diabetes mellitus and multivessel disease undergoing coronary revascularization: Results from the FREEDOM trial. Int J Cardiol. 2019 10 15; 293:197-202.
    View in: PubMed
    Score: 0.019
  55. Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS Registry. JACC Cardiovasc Interv. 2019 05 27; 12(10):983-992.
    View in: PubMed
    Score: 0.018
  56. Residual Inflammatory Risk in Patients With Low LDL Cholesterol Levels Undergoing Percutaneous Coronary Intervention. J Am Coll Cardiol. 2019 05 21; 73(19):2401-2409.
    View in: PubMed
    Score: 0.018
  57. Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2019 04; 12(4):e007133.
    View in: PubMed
    Score: 0.018
  58. Outcomes by Gender and Ethnicity After Percutaneous Coronary Intervention. Am J Cardiol. 2019 06 15; 123(12):1941-1948.
    View in: PubMed
    Score: 0.018
  59. Temporal Trends in Statin Prescriptions and Residual Cholesterol Risk in Patients With Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. Am J Cardiol. 2019 06 01; 123(11):1788-1795.
    View in: PubMed
    Score: 0.018
  60. Calculated Serum Osmolality, Acute Kidney Injury, and Relationship to Mortality after Percutaneous Coronary Intervention. Cardiorenal Med. 2019; 9(3):160-167.
    View in: PubMed
    Score: 0.018
  61. Frequency of 30-day readmission and its causes after percutaneous coronary intervention in acute myocardial infarction complicated by cardiogenic shock. Catheter Cardiovasc Interv. 2019 Aug 01; 94(2):E67-E77.
    View in: PubMed
    Score: 0.018
  62. Safety and Efficacy of Polymer-Free Drug-Eluting Stents. Circ Cardiovasc Interv. 2019 02; 12(2):e007311.
    View in: PubMed
    Score: 0.018
  63. Safety and efficacy of the COMBO bio-engineered stent in an all-comer PCI cohort: 1-Year final clinical outcomes from the MASCOT post-marketing registry. Int J Cardiol. 2019 05 15; 283:67-72.
    View in: PubMed
    Score: 0.018
  64. Use of prasugrel and clinical outcomes in African-American patients treated with percutaneous coronary intervention for acute coronary syndromes. Catheter Cardiovasc Interv. 2019 Jul 01; 94(1):53-60.
    View in: PubMed
    Score: 0.018
  65. Incidence, predictors, and outcomes of DAPT disruption due to non-compliance vs. bleeding after PCI: insights from the PARIS Registry. Clin Res Cardiol. 2019 Jun; 108(6):643-650.
    View in: PubMed
    Score: 0.018
  66. Residual inflammatory risk and the impact on clinical outcomes in patients after percutaneous coronary interventions. Eur Heart J. 2018 12 07; 39(46):4101-4108.
    View in: PubMed
    Score: 0.018
  67. Patterns and Impact of Dual Antiplatelet Cessation on Cardiovascular Risk After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes. Am J Cardiol. 2019 03 01; 123(5):709-716.
    View in: PubMed
    Score: 0.018
  68. Predictors of side branch compromise in calcified bifurcation lesions treated with orbital atherectomy. Catheter Cardiovasc Interv. 2019 07 01; 94(1):45-52.
    View in: PubMed
    Score: 0.018
  69. Use of prasugrel vs clopidogrel and outcomes in patients with and without diabetes mellitus presenting with acute coronary syndrome undergoing percutaneous coronary intervention. Int J Cardiol. 2019 Jan 15; 275:31-35.
    View in: PubMed
    Score: 0.018
  70. The prevalence, predictors and outcomes of guideline-directed medical therapy in patients with acute myocardial infarction undergoing PCI, an analysis from the PROMETHEUS registry. Catheter Cardiovasc Interv. 2019 02 15; 93(3):E112-E119.
    View in: PubMed
    Score: 0.018
  71. Determinants of Significant Out-Of-Hospital Bleeding in Patients Undergoing Percutaneous Coronary Intervention. Thromb Haemost. 2018 Nov; 118(11):1997-2005.
    View in: PubMed
    Score: 0.018
  72. 1-Year Clinical Outcomes of All-Comer Patients Treated With the Dual-Therapy COMBO Stent: Primary Results of the COMBO Collaboration. JACC Cardiovasc Interv. 2018 10 08; 11(19):1969-1978.
    View in: PubMed
    Score: 0.018
  73. Intravascular Brachytherapy for the Management of Repeated Multimetal-Layered Drug-Eluting Coronary Stent Restenosis. Circ Cardiovasc Interv. 2018 10; 11(10):e006832.
    View in: PubMed
    Score: 0.018
  74. Temporal trends, determinants, and impact of high-intensity statin prescriptions after percutaneous coronary intervention: Results from a large single-center prospective registry. Am Heart J. 2019 01; 207:10-18.
    View in: PubMed
    Score: 0.018
  75. Carotid plaque thickness and carotid plaque burden predict future cardiovascular events in asymptomatic adult Americans. Eur Heart J Cardiovasc Imaging. 2018 09 01; 19(9):1042-1050.
    View in: PubMed
    Score: 0.018
  76. Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry). Am J Cardiol. 2018 11 15; 122(10):1638-1646.
    View in: PubMed
    Score: 0.018
  77. Real-World Bioresorbable Vascular Scaffold Experience Compared With Second-Generation Metallic Drug-Eluting Stents in Complex Coronary Lesions. J Invasive Cardiol. 2018 07; 30(7):251-255.
    View in: PubMed
    Score: 0.017
  78. Effect of Increasing Stent Length on 3-Year Clinical Outcomes in Women Undergoing Percutaneous Coronary Intervention With New-Generation Drug-Eluting Stents: Patient-Level Pooled Analysis of Randomized Trials From the WIN-DES Initiative. JACC Cardiovasc Interv. 2018 01 08; 11(1):53-65.
    View in: PubMed
    Score: 0.017
  79. Associations Between Complex PCI and Prasugrel or Clopidogrel Use in Patients With Acute Coronary Syndrome Who Undergo PCI: From the PROMETHEUS Study. Can J Cardiol. 2018 03; 34(3):319-329.
    View in: PubMed
    Score: 0.017
  80. Effects of Body Mass Index on Clinical Outcomes in Female Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From a Patient-Level Pooled Analysis of Randomized Controlled Trials. JACC Cardiovasc Interv. 2018 01 08; 11(1):68-76.
    View in: PubMed
    Score: 0.017
  81. Sex differences in the effect of diabetes mellitus on platelet reactivity and coronary thrombosis: From the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents (ADAPT-DES) study. Int J Cardiol. 2017 Nov 01; 246:20-25.
    View in: PubMed
    Score: 0.017
  82. Prognostic Relation Between Severity of Diabetes Mellitus (On or Off Insulin)?±?Chronic Kidney Disease with Cardiovascular Risk After Percutaneous Coronary Intervention. Am J Cardiol. 2018 01 15; 121(2):168-176.
    View in: PubMed
    Score: 0.017
  83. White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry). Circ Cardiovasc Interv. 2017 Sep; 10(9).
    View in: PubMed
    Score: 0.016
  84. Antithrombotic potency of ticagrelor versus clopidogrel in type-2 diabetic patients with cardiovascular disease. Thromb Haemost. 2017 10 05; 117(10):1981-1988.
    View in: PubMed
    Score: 0.016
  85. Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. JAMA Cardiol. 2017 08 01; 2(8):855-862.
    View in: PubMed
    Score: 0.016
  86. Intracoronary Imaging, Cholesterol Efflux, and Transcriptomics after Intensive Statin Treatment in Diabetes. Sci Rep. 2017 08 01; 7(1):7001.
    View in: PubMed
    Score: 0.016
  87. Impact of Timing on the Functional Recovery Achieved With Platelet Supplementation After Treatment With Ticagrelor. Circ Cardiovasc Interv. 2017 08; 10(8).
    View in: PubMed
    Score: 0.016
  88. Prevalence, correlates, and impact of coronary calcification on adverse events following PCI with newer-generation DES: Findings from a large multiethnic registry. Catheter Cardiovasc Interv. 2018 04 01; 91(5):859-866.
    View in: PubMed
    Score: 0.016
  89. Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of Non-adherence to Anti-platelet Regimens In Stented Patients Registry). Am J Cardiol. 2017 Sep 15; 120(6):904-910.
    View in: PubMed
    Score: 0.016
  90. Mid-term outcomes of consecutive 998 cases of coronary atherectomy in contemporary clinical practice. J Interv Cardiol. 2017 Aug; 30(4):331-337.
    View in: PubMed
    Score: 0.016
  91. Three-dimensional volumetric assessment of coronary artery calcification in patients with stable coronary artery disease by OCT. EuroIntervention. 2017 Jun 20; 13(3):312-319.
    View in: PubMed
    Score: 0.016
  92. Patterns and associations between DAPT cessation and 2-year clinical outcomes in left main/proximal LAD versus other PCI: Results from the Patterns of Non-Adherence to Dual Antiplatelet Therapy in Stented Patients (PARIS) registry. Int J Cardiol. 2017 Sep 15; 243:132-139.
    View in: PubMed
    Score: 0.016
  93. Increased Lipid Length, Macrophage Infiltration, and Neovascularization in Coronary Atheroma From Patients With Chronic Kidney Disease. JACC Cardiovasc Imaging. 2017 12; 10(12):1524-1526.
    View in: PubMed
    Score: 0.016
  94. Clinical and angiographic predictors of haemodynamically significant angiographic lesions: development and validation of a risk score to predict positive fractional flow reserve. EuroIntervention. 2017 Apr 07; 12(18):e2228-e2235.
    View in: PubMed
    Score: 0.016
  95. Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS Registry. JACC Cardiovasc Interv. 2017 04 10; 10(7):645-654.
    View in: PubMed
    Score: 0.016
  96. An Algorithm for the Use of Embolic Protection During Atherectomy for Femoral Popliteal Lesions. JACC Cardiovasc Interv. 2017 02 27; 10(4):403-410.
    View in: PubMed
    Score: 0.016
  97. Polygenic Risk Score Identifies Subgroup With Higher Burden of Atherosclerosis and Greater Relative Benefit From Statin Therapy in the Primary Prevention Setting. Circulation. 2017 May 30; 135(22):2091-2101.
    View in: PubMed
    Score: 0.016
  98. Quantitative angiographic characterisation of coronary artery disease in patients with human immunodeficiency virus (HIV) infection undergoing percutaneous coronary intervention. EuroIntervention. 2017 Feb 20; 12(14):1757-1765.
    View in: PubMed
    Score: 0.016
  99. Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents). Circ Cardiovasc Interv. 2017 02; 10(2).
    View in: PubMed
    Score: 0.016
  100. Impact of Diabetes Mellitus on Ischemic Events in Men and Women After Percutaneous Coronary Intervention. Am J Cardiol. 2017 04 15; 119(8):1166-1172.
    View in: PubMed
    Score: 0.016
  101. Evaluation of the Pooled Cohort Equations for Prediction of Cardiovascular Risk in a Contemporary Prospective Cohort. Am J Cardiol. 2017 Mar 15; 119(6):881-885.
    View in: PubMed
    Score: 0.016
  102. Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease. N Engl J Med. 2016 12 15; 375(24):2349-2358.
    View in: PubMed
    Score: 0.016
  103. Gender Differences in Associations Between Intraprocedural Thrombotic Events During Percutaneous Coronary Intervention and Adverse Outcomes. Am J Cardiol. 2016 Dec 01; 118(11):1661-1668.
    View in: PubMed
    Score: 0.015
  104. Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. JACC Cardiovasc Interv. 2016 09 26; 9(18):1890-901.
    View in: PubMed
    Score: 0.015
  105. Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry. Catheter Cardiovasc Interv. 2017 Jun 01; 89(7):E217-E225.
    View in: PubMed
    Score: 0.015
  106. Complex association of serum alanine aminotransferase with the risk of future cardiovascular disease in type 2 diabetes. Atherosclerosis. 2016 11; 254:42-51.
    View in: PubMed
    Score: 0.015
  107. A Simple Disease-Guided Approach to Personalize ACC/AHA-Recommended Statin Allocation in Elderly People: The BioImage Study. J Am Coll Cardiol. 2016 08 30; 68(9):881-91.
    View in: PubMed
    Score: 0.015
  108. Impact of an integrated treatment algorithm based on platelet function testing and clinical risk assessment: results of the TRIAGE Patients Undergoing Percutaneous Coronary Interventions To Improve Clinical Outcomes Through Optimal Platelet Inhibition study. J Thromb Thrombolysis. 2016 Aug; 42(2):186-96.
    View in: PubMed
    Score: 0.015
  109. Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With Stents. JACC Cardiovasc Interv. 2016 07 25; 9(14):1461-9.
    View in: PubMed
    Score: 0.015
  110. Enhanced neointimal fibroblast, myofibroblast content and altered extracellular matrix composition: Implications in the progression of human peripheral artery restenosis. Atherosclerosis. 2016 08; 251:226-233.
    View in: PubMed
    Score: 0.015
  111. Exome sequencing of extreme clopidogrel response phenotypes identifies B4GALT2 as a determinant of on-treatment platelet reactivity. Clin Pharmacol Ther. 2016 09; 100(3):287-94.
    View in: PubMed
    Score: 0.015
  112. Sex-related differences in outcomes among men and women under 55 years of age with acute coronary syndrome undergoing percutaneous coronary intervention: Results from the PROMETHEUS study. Catheter Cardiovasc Interv. 2017 Mar 01; 89(4):629-637.
    View in: PubMed
    Score: 0.015
  113. Resistant in-stent restenosis in the drug eluting stent era. Catheter Cardiovasc Interv. 2016 Nov; 88(5):777-785.
    View in: PubMed
    Score: 0.015
  114. Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization: From the WIN-DES Collaborative Patient-Level Pooled Analysis. JACC Cardiovasc Interv. 2016 Apr 11; 9(7):674-84.
    View in: PubMed
    Score: 0.015
  115. Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. Am J Cardiol. 2016 Jun 15; 117(12):1877-83.
    View in: PubMed
    Score: 0.015
  116. Multimodality Intravascular Imaging to Evaluate Sex Differences in Plaque Morphology in Stable CAD. JACC Cardiovasc Imaging. 2016 Apr; 9(4):400-7.
    View in: PubMed
    Score: 0.015
  117. Digital Mammography and Screening for Coronary Artery Disease. JACC Cardiovasc Imaging. 2016 Apr; 9(4):350-60.
    View in: PubMed
    Score: 0.015
  118. Plaque morphology predictors of side branch occlusion after provisional stenting in coronary bifurcation lesion: Results of optical coherence tomography bifurcation study (ORBID). Catheter Cardiovasc Interv. 2017 Feb 01; 89(2):259-268.
    View in: PubMed
    Score: 0.015
  119. Relation Between Platelet Count and Platelet Reactivity to Thrombotic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. Am J Cardiol. 2016 Jun 01; 117(11):1703-13.
    View in: PubMed
    Score: 0.015
  120. Relation of Internal Elastic Lamellar Layer Disruption to Neointimal Cellular Proliferation and Type III Collagen Deposition in Human Peripheral Artery Restenosis. Am J Cardiol. 2016 Apr 01; 117(7):1173-9.
    View in: PubMed
    Score: 0.015
  121. Safety and Efficacy of New-Generation Drug-Eluting Stents in Women at High Risk for Atherothrombosis: From the Women in Innovation and Drug-Eluting Stents Collaborative Patient-Level Pooled Analysis. Circ Cardiovasc Interv. 2016 Jan; 9(1):e002995.
    View in: PubMed
    Score: 0.015
  122. Association of APOC3 Loss-of-Function Mutations With Plasma Lipids and Subclinical Atherosclerosis: The Multi-Ethnic BioImage Study. J Am Coll Cardiol. 2015 Nov 03; 66(18):2053-2055.
    View in: PubMed
    Score: 0.014
  123. One-year results of the ICON (Ionic versus non-ionic Contrast to Obviate worsening Nephropathy after angioplasty in chronic renal failure patients) Study. Catheter Cardiovasc Interv. 2016 Mar; 87(4):703-9.
    View in: PubMed
    Score: 0.014
  124. Antithrombotic strategy variability in ATrial fibrillation and obstructive coronary disease revascularized with PCI-rationale and study design of the prospective observational multicenter AVIATOR 2 registry. Am Heart J. 2015 Dec; 170(6):1234-42.
    View in: PubMed
    Score: 0.014
  125. Incremental prognostic value of coronary computed tomographic angiography high-risk plaque characteristics in newly symptomatic patients. J Cardiol. 2016 06; 67(6):538-44.
    View in: PubMed
    Score: 0.014
  126. Impact of Contrast-Induced Acute Kidney Injury After Percutaneous Coronary Intervention on Short- and Long-Term Outcomes: Pooled Analysis From the HORIZONS-AMI and ACUITY Trials. Circ Cardiovasc Interv. 2015 Aug; 8(8):e002475.
    View in: PubMed
    Score: 0.014
  127. Incidence and impact of acute kidney injury in patients with acute coronary syndromes treated with coronary artery bypass grafting: Insights from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) and Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trials. Am Heart J. 2016 Jan; 171(1):40-7.
    View in: PubMed
    Score: 0.014
  128. Impact of Clinical Presentation (Stable Angina Pectoris vs Unstable Angina Pectoris or Non-ST-Elevation Myocardial Infarction vs ST-Elevation Myocardial Infarction) on Long-Term Outcomes in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. Am J Cardiol. 2015 Sep 15; 116(6):845-52.
    View in: PubMed
    Score: 0.014
  129. Multimodality Intravascular Imaging to Predict Periprocedural Myocardial Infarction During Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2015 Jun; 8(7):937-45.
    View in: PubMed
    Score: 0.014
  130. Optical coherence tomography assessment of the mechanistic effects of rotational and orbital atherectomy in severely calcified coronary lesions. Catheter Cardiovasc Interv. 2015 Nov 15; 86(6):1024-32.
    View in: PubMed
    Score: 0.014
  131. Balancing the Risk of Bleeding and Stroke in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the AVIATOR Registry). Am J Cardiol. 2015 Jul 01; 116(1):37-42.
    View in: PubMed
    Score: 0.014
  132. Comparison of provisional 1-stent and 2-stent strategies in diabetic patients with true bifurcation lesions: the EES bifurcation study. J Invasive Cardiol. 2014 Dec; 26(12):619-23.
    View in: PubMed
    Score: 0.014
  133. Contrasting Cholesterol Management Guidelines for Adults with CKD. J Am Soc Nephrol. 2015 May; 26(5):1173-80.
    View in: PubMed
    Score: 0.013
  134. Outcomes of patients calling emergency medical services for suspected acute cardiovascular disease. Am J Cardiol. 2015 Jan 01; 115(1):13-20.
    View in: PubMed
    Score: 0.013
  135. The relationship among extent of lipid-rich plaque, lesion characteristics, and plaque progression/regression in patients with coronary artery disease: a serial near-infrared spectroscopy and intravascular ultrasound study. Eur Heart J Cardiovasc Imaging. 2015 Jan; 16(1):81-7.
    View in: PubMed
    Score: 0.013
  136. A simple scoring tool for the evaluation of patients in an emergency department chest pain unit. Conn Med. 2014 Sep; 78(8):465-74.
    View in: PubMed
    Score: 0.013
  137. Dedicated two-stent technique in complex bifurcation percutaneous coronary intervention with use of everolimus-eluting stents: the EES-bifurcation study. Int J Cardiol. 2014 Jun 01; 174(1):13-7.
    View in: PubMed
    Score: 0.013
  138. A comparison of coronary CTA and stress testing using high-efficiency SPECT MPI for the evaluation of chest pain in the emergency department. J Nucl Cardiol. 2014 Apr; 21(2):305-18.
    View in: PubMed
    Score: 0.013
  139. Clustering of acute and subacute stent thrombosis related to the introduction of generic clopidogrel. J Cardiovasc Pharmacol Ther. 2014 Mar; 19(2):201-8.
    View in: PubMed
    Score: 0.013
  140. Increased thin-cap neoatheroma and periprocedural myocardial infarction in drug-eluting stent restenosis: multimodality intravascular imaging of drug-eluting and bare-metal stents. Circ Cardiovasc Interv. 2013 Oct 01; 6(5):507-17.
    View in: PubMed
    Score: 0.012
  141. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet. 2013 Nov 23; 382(9906):1714-22.
    View in: PubMed
    Score: 0.012
  142. Coronary artery calcification is inversely related to body morphology in patients with significant coronary artery disease: a three-dimensional intravascular ultrasound study. Eur Heart J Cardiovasc Imaging. 2014 Feb; 15(2):201-9.
    View in: PubMed
    Score: 0.012
  143. Comparison of six risk scores in patients with triple vessel coronary artery disease undergoing PCI: competing factors influence mortality, myocardial infarction, and target lesion revascularization. Catheter Cardiovasc Interv. 2013 Nov 15; 82(6):855-68.
    View in: PubMed
    Score: 0.012
  144. High-efficiency SPECT MPI: comparison of automated quantification, visual interpretation, and coronary angiography. J Nucl Cardiol. 2013 Oct; 20(5):763-73.
    View in: PubMed
    Score: 0.012
  145. Changes in plaque lipid content after short-term intensive versus standard statin therapy: the YELLOW trial (reduction in yellow plaque by aggressive lipid-lowering therapy). J Am Coll Cardiol. 2013 Jul 02; 62(1):21-9.
    View in: PubMed
    Score: 0.012
  146. Safety and efficacy of high- versus low-dose aspirin after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. JACC Cardiovasc Interv. 2012 Dec; 5(12):1231-8.
    View in: PubMed
    Score: 0.012
  147. A model for the prediction of a successful stress-first Tc-99m SPECT MPI. J Nucl Cardiol. 2012 Dec; 19(6):1124-34.
    View in: PubMed
    Score: 0.012
  148. Genotype-dependent impairment of hemoglobin clearance increases oxidative and inflammatory response in human diabetic atherosclerosis. Arterioscler Thromb Vasc Biol. 2012 Nov; 32(11):2769-75.
    View in: PubMed
    Score: 0.012
  149. High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study. JACC Cardiovasc Imaging. 2012 May; 5(5):540-9.
    View in: PubMed
    Score: 0.011
  150. Inverse relationship between body mass index and coronary artery calcification in patients with clinically significant coronary lesions. Atherosclerosis. 2012 Mar; 221(1):176-82.
    View in: PubMed
    Score: 0.011
  151. Female gender and mortality after percutaneous coronary intervention: results from a large registry. Catheter Cardiovasc Interv. 2012 Oct 01; 80(4):514-21.
    View in: PubMed
    Score: 0.011
  152. Impact of in-hospital major bleeding on late clinical outcomes after primary percutaneous coronary intervention in acute myocardial infarction the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. J Am Coll Cardiol. 2011 Oct 18; 58(17):1750-6.
    View in: PubMed
    Score: 0.011
  153. Association of the metabolic syndrome with atrial fibrillation among United States adults (from the REasons for Geographic and Racial Differences in Stroke [REGARDS] Study). Am J Cardiol. 2011 Jul 15; 108(2):227-32.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.